MARKETVUE® REPORT: Over 80% of Tardive Dyskinesia patients are currently prescribed Austedo or Ingrezza, according to U.S. Neurologists
U.S. physicians report that the majority of their patients on Teva Pharmaceuticals’ Austedo and Neurocrine Biosciences’ Ingrezza achieve some degree of symptom relief, according to findings from REACH Market Research. [...]
MARKETVUE® REPORT: Surgery remains the only option for the ~50% of LQTS patients refractory or intolerant to beta blockers
LQTS types 2 and 3 have the highest need for novel pharmacologic treatments of all subtypes, according to findings from REACH Market Research. NEWTON, Mass., Nov. 7, 2023 /PRNewswire/ -- Long QT syndrome [...]
MARKETVUE® REPORT: Arrhythmogenic Cardiomyopathy Gene Therapy Research Gains Momentum
~70% of physicians surveyed by REACH Market Research report there is an extremely high unmet medical need for novel treatments for ACM. NEWTON, Mass., Nov. 7, 2023 /PRNewswire/ -- Arrhythmogenic Cardiomyopathy (ACM) is [...]
MARKETVUE® REPORT: Gene therapies for treatment of Glycogen Storage Disease Type 1a offer hope for overburdened patients
Ultragenyx's AAV8 vector gene therapy, DTX401, is advancing through clinical trials as potentially the first ever therapy to treat Glycogen Storage Disease Type 1a (GSD-1a). NEWTON, Mass., Sept. 28, 2023 /PRNewswire/ -- [...]
MARKETVUE® REPORT: Over 80% of Tardive Dyskinesia patients are currently prescribed Austedo or Ingrezza, according to U.S. Neurologists
U.S. physicians report that the majority of their patients on Teva Pharmaceuticals’ Austedo and Neurocrine Biosciences’ Ingrezza achieve some degree of symptom relief, according to findings from REACH Market Research. [...]
MARKETVUE® REPORT: Surgery remains the only option for the ~50% of LQTS patients refractory or intolerant to beta blockers
LQTS types 2 and 3 have the highest need for novel pharmacologic treatments of all subtypes, according to findings from REACH Market Research. NEWTON, Mass., Nov. 7, 2023 /PRNewswire/ -- Long QT syndrome [...]
MARKETVUE® REPORT: Arrhythmogenic Cardiomyopathy Gene Therapy Research Gains Momentum
~70% of physicians surveyed by REACH Market Research report there is an extremely high unmet medical need for novel treatments for ACM. NEWTON, Mass., Nov. 7, 2023 /PRNewswire/ -- Arrhythmogenic Cardiomyopathy (ACM) is [...]
MARKETVUE® REPORT: Gene therapies for treatment of Glycogen Storage Disease Type 1a offer hope for overburdened patients
Ultragenyx's AAV8 vector gene therapy, DTX401, is advancing through clinical trials as potentially the first ever therapy to treat Glycogen Storage Disease Type 1a (GSD-1a). NEWTON, Mass., Sept. 28, 2023 /PRNewswire/ -- [...]